header image

Page 18«..10..17181920..3040..»

Archive for Pet Stem Cell Therapy

From sci-fi to reality: a peek into the future of medicine – British Heart Foundation

From heart transplants to implantable devices, BHF-funded science has helped to develop innovations that once seems like science fiction. Heres a preview of what the future of medicine might bring next.

Around one in every 200 newborn babies has a heart problem that needs surgery or another procedure. Professor John Simpson and his team at Evelina London Childrens Hospital and Kings College London are using a BHF grant to work on a virtual reality technology to improve these procedures.

He explains: We look at detailed scan images of an individuals heart in order to decide what is the right procedure, at the right time, with the minimum risk.

In the last couple of decades, weve gone from 2D to 3D images. But youre still looking at them on a flat screen. Even 3D printed models of hearts are not perfect you have to break it to see the structures inside. Also, the 3D models show the heart at one moment in time. But the living heart is dynamic; it beats, and the valves open and close.

With his teams new technology, information from heart scans routinely taken in hospitals can be turned into a virtual, beating heart. With the headset on, and joystick in your hand, the virtual heart is right in front of you. You can zoom in and out, see it from every angle and look inside, says Dr Natasha Stephenson, Professor Simpsons fellow researcher.

In a previous study, surgeons used the technology to review operations that had already taken place. They found that, compared to traditional 3D imaging, it gave them a better understanding of the patients heart and would have helped them better plan the surgeries. Now the team are working towards testing this technology to plan real procedures, which they hope to do in the next two years.

This technology allows surgeons to understand what theyll actually face in the operation, says Professor Simpson. You can put a virtual device into the virtual heart and see which will be the best device. Or even share the imaging with companies that can make bespoke devices to fit the individuals heart. We hope this will mean better repairs, fewer complications, shorter hospital stays and better long-term outcomes.

These virtual reality images can also be used to show patients what the issues are with their heart, or used to train doctors.

While Professor Simpsons focus is on congenital heart diseases, he says, In the long term, this technology could also help better visualise the problems of adults with other types of heart disease.

Sign up to our fortnightly Heart Matters newsletter to receive healthy recipes, new activity ideas, and expert tips for managing your health. Joining is free and takes two minutes.

After a heart attack, some heart muscle cells can die off, which can lead to heart failure. Dr Nicola Smart is trying to answer questions that might one day help us to help hearts regrow themselves.

From studies in mice, we know a couple of days after birth, the heart can fully regenerate. A week after birth, it loses that ability, explains Dr Smart.

To repair itself, the heart needs to grow new blood vessels, as well as new muscle. In adults, there is some growth of blood vessels, but it happens slowly and inefficiently.

She and her team at the University of Oxford are studying how different types of cells in different parts of the heart send signals to each other, helping the heart to grow new blood vessels. Through a technique called single-cell RNA-sequencing, she is seeing which of the genes involved in this process are switched off (not expressed) in adults.

Single-cell RNA-sequencing has completely changed our level of understanding. It used to be that we could only look at overall gene expression changes in a heart. That could tell you nothing about how different cells were responding to a heart attack. Now we see which genes are being expressed in each cell, we know even the same types of cells will respond differently in different parts of the heart.

Dr Smart says were just at the start of understanding how this new knowledge might lead to treatments in future. Regrowing heart muscle and blood vessels is only one part. Other teams are looking at how to limit scarring and how to work with the immune system, which also influences the hearts ability to regenerate. But if we can bring together all these ideas, we could develop a combination therapy to stimulate the heart to regenerate, and that could prevent more people developing heart failure.

Scarring is part of the bodys healing process. But it can cause problems. After a heart attack, too much scarring can stop the heart working well and cause heart failure.

MRI scansare currently used to look at scars that have already formed in peoples hearts. Now BHF-funded research is developing a cutting-edge technique so doctors can track scarring as it happens.

Professor Marc Dweck and his team at the University of Edinburgh are using PET scanning, a type of very detailed scan that can show how your bodys cells are working. Were using a new tracer a special chemical, which attaches to cells that cause scarring. The tracer sends a signal that we can detect on the scan.

Right now, we dont have a clear idea of when scarring occurs following a heart attack. In people who develop heart failure, do they have too much scarring activity or is it that scarring doesnt turn off at the right time?

His team will try to find the answers by studying people whove recently had heart attacks, as well as people who have old scarring from previous heart attacks, and healthy people.

Understanding how scarring develops may help us predict who will make a good recovery after a heart attack and who will need more treatment to prevent heart failure, explains Professor Dweck. Were talking precision medicine: with better scanning, we can tailor the right treatment to the right patient.

Pulmonary arterial hypertension (PAH) is a rare but serious condition, which causes high blood pressure in the arteries of the lungs. It can lead to heart failure and can sometimes be fatal. Currently there is no cure. BHF-funded researcher Alex Ainscough, at Imperial College London, is developing a new way to look for treatments.

He's created a pulmonary artery on a chip, in which the innermost layers of the artery walls are recreated inside a silicone rubber microchip just 1mm wide (the same size as the small arteries that are first affected in PAH).

In traditional research, you look at one type of cell, but in our bodies different cell types interact with each other, explains Dr Ainscough. We are trying to make it as representative of the human body as possible.

By running liquid through the chip, he can mimic the flow of blood in the body, which has a big impact on the cells. He explains: When you grow cells in a petri dish for research, its like theyre in the calm of a lake; but in the body, they are being subjected to forces like a fast-flowing stream.

He created a model of a diseased artery by using stem cells from people with PAH to create a pulmonary artery on a chip, which led to him discovering a previously unknown way in which PAH develops.

As well as being used as an investigative tool to understand how PAH happens, the pulmonary artery on a chip is being used to try out potential treatments. Dr Ainscough is working with a pharmaceutical company to test some of their existing drugs, as well as new drugs that are in development to treat PAH.

He predicts that in future, organ-on-a-chip models will help make treatments cheaper and quicker to develop. These models more closely match conditions in people compared to traditional petri dish research, so it will be faster to identify promising drugs before moving to clinical trials.

Theres also potential to use these for more personalised medicine. You could use stem cells from a particular person to create a microchip model to see how theyll react to a specific drug before giving it to them.

Most babies having surgery for heart defects will need repairs using additional materials such as patches, valves or tubes. These products are either made from animal tissue or synthetic material: they wont grow with the child and will become scar tissue and gradually deteriorate.

Massimo Caputo, BHF Professor of Congenital Heart Surgery at the University of Bristol, explains: This means a child might need surgery weeks after theyre born, again after a year or two, then after another five years, and carry on having repeated surgeries all their lives.

Each surgery can cause more scarring, which can cause problems like heart failureor abnormal heart rhythms. Theres also the mental stress of going through these operations. For years, patients and parents have said to me, Why cant we have a valve that lasts forever?

Thanks to one of our research grants, Professor Caputo is developing a kind of living tissue, made partly from stem cells, that will grow with the child. Hes currently in the process of securing regulatory approval and the first tests in patients should start in two to three years.

This living tissue could reduce the need for multiple surgeries, in adults as well as children. If you have a valve replacement from animal tissue, this will wear down and you will need to replace it after 10 years. Even if youre in your 50s or 60s, that could mean multiple surgeries. The tissue Im working on could be applied to adult surgery too, says Professor Caputo.

Another benefit is that this tissue could be less likely to be rejected by the body: A patients own stem cells could be used to produce the tissue, so that the immune system recognises it and doesnt reject it.

Published 10 June 2022

Continued here:
From sci-fi to reality: a peek into the future of medicine - British Heart Foundation

Has Another Restaurant Show Come to Loveland to Make People Cry? – Retro 102.5

A couple of 'restaurant' shows have come to Loveland in the last year, and now it seems as though another one is here to do their thing.

It was in October of 2021, that 'Restaurant Impossible' came to Loveland to help out Casa Real. They did make improvements, though not everyone was keen on what they did.

It's fun when a television show comes to your hometown to film. I grew up in Loveland, and still get giddy when these stories come out. 'OOH! A TV star is coming to Loveland! Cool!' How many different cities/towns do these shows go to, all the time, and face 'yocals' like me? It must be in the hundreds.

Downtown Loveland's The Ball Joint was on The Cooking Channel's 'Food Paradise' in February of 2022, and really gave them a shot in the arm. Publicity, in the form of being on TV, does go a long way. The Ball Joint, however, was just showcasing their unique menu, they weren't getting advice or a renovation.

This new visit sounds like advice and a renovation.

It sounds like Jon Taffer and the gang at Bar Rescue are coming into to help out a long time eatery.I've eaten there, had drinks there, many times. It's a very friendly place with good food. CJ's Patio Grill.

I checked out there Facebook page when I got the lead, and they are indeed closing for a few days.

CJ's-Patio-Grill-Closed

I went over to CJ's on the morning of June 7, 2022. The parking lot had about a dozen parking spaces blocked off around the perimeter of the lot, and a some staffers were seated outside. A staffer saw me walking up to take a photo; we had a discussion:

We're closed.

I heard that Bar Rescue is coming, is that true?

I can't say... Non-Disclosure Agreement...

Here we are with another 'NDA' for the Fort Collins area.Interesting, no? I hope that things aren't in terrible shape for CJ's; I've seen Bar Rescue, and when Jon comes to your place, he's going to get in somebody's face, probably yours.

In the end, it's going to be great to get in there and see that they changed. I have a few ideas on what they might do, design wise. Hopefully, everybody walks away happy, with little tears shed.

CJ's-Patio-Grill-Loveland

As Loveland looks at 2022, let's look at 22 things the city could use.

Some of these joints have been gone for decades; a few, not that long.

To prepare yourself for a potential incident, always keep your vet's phone number handy, along with an after-hours clinic you can call in an emergency. The ASPCA Animal Poison Control Center also has a hotline you can call at (888) 426-4435 for advice.

Even with all of these resources, however, the best cure for food poisoning is preventing it in the first place. To give you an idea of what human foods can be dangerous, Stacker has put together a slideshow of 30 common foods to avoid. Take a look to see if there are any that surprise you.

Go here to read the rest:
Has Another Restaurant Show Come to Loveland to Make People Cry? - Retro 102.5

MD Anderson researchers present cellular therapy advances at the 2022 ASCO Annual Meeting – EurekAlert

ABSTRACTS 7518, 7509, 8009

Promising clinical results with cellular therapies for patients with blood cancers highlight advances being presented by researchers from The University of Texas MD Anderson Cancer Center at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting.

These findings include long-term outcomes of patients receiving an infusion of brexucabtagene autoleucel (KTE-X19) for mantle cell lymphoma, efficacy of gamma delta CAR T therapy for aggressive B-cell lymphoma and responses of umbilical cord blood-derived expanded natural killer cells when given together with combination therapy before stem cell transplant.

CAR T cell therapy shows durable responses after three years for patients with mantle cell lymphoma (Abstract 7518)Three-year follow-up data from the Phase II ZUMA-2 trial showed a long-term survival benefit and low disease relapse potential with one infusion of the anti-CD19 chimeric antigen receptor (CAR) T cell therapy brexucabtagene autoleucel (KTE-X19) in patients with relapsed or refractory (R/R) mantle cell lymphoma (MCL). Principal investigator Michael Wang, M.D., professor of Lymphoma and Myeloma, presented results from the trial, and study results were published in the Journal of Clinical Oncology.

The updated results include all 68 patients treated with KTE-X19 on the trial with an additional two years of follow-up. After 35.6 months median follow-up, the overall response rate was 91%, with a 68% complete response rate. The median duration of response was 28.2 months, with 25 of 68 treated patients still in ongoing response at data cutoff.

This represents the longest follow-up of CAR T cell therapy in patients with mantle cell lymphoma to date, Wang said. It is encouraging to see this therapy induced durable long-term responses and a low relapse rate for these patients.

All patients had R/R disease after receiving up to five therapies, and all had received previous Brutons tyrosine kinase (BTK) inhibitor therapy. BTK inhibitors have greatly improved outcomes in R/R MCL, yet patients who have subsequent disease progression are likely to have poor outcomes, with median overall survival of just six to 10 months. Few patients in this category qualify to proceed to an allogeneic stem cell transplant.

Response and survival benefits were positive regardless of the prior BTK inhibitor type. Ongoing effectiveness trended lower in patients with prior acalabrutinib exposure. More investigation is needed to determine the mechanism behind these differences. The findings support future study of CD19-directed CAR T cell therapy in patients with high-risk MCL in earlier treatment lines.

The researchers also evaluated minimal residual disease (MRD) as an exploratory endpoint using next-generation sequencing on 29 patients. Of those, 24 were MRD-negative at one month, and 15 of 19 with available data were MRD-negative at six months. Circulating tumor DNA analysis of MRD at three and six months was predictive of disease relapse.

The treatment was well tolerated, as reported in previous studies with this therapy. Only 3% of treatment-emergent adverse events (AE) of interest occurred since the primary report. The most frequent Grade 3 AE was neutropenia.

The study was funded by Kite Pharma, a Gilead Company. Wang has received research support and has served on the advisory board and as a consultant for Kite Pharma. A complete list of collaborating authors can be found within the abstract here.

Allogeneic gamma delta CAR T cell therapy displayed encouraging efficacy in B-cell lymphoma (Abstract 7509)In the Phase 1 GLEAN trial of ADI-001, an anti-CD20 CAR-engineered allogeneic gamma delta T cell product, the treatment was well tolerated and showed continued efficacy in patients with R/R aggressive B-cell lymphoma. Results from the ongoing trial were presented by Sattva Neelapu, M.D., professor ofLymphoma and Myeloma.

The first-in-human trial enrolled ten patients and eight were evaluable and monitored for at least 28 days. The median age was 62 years and patients received a median of 4 prior therapies. At Day 28, the overall response rate (ORR) and complete response (CR) rate based upon PET/CT was 75%. The ORR and CR rate was 80% at dose levels two and three combined. The ORR and CR rate in CAR-T relapsed patients was 100%.

The responses to ADI-001 in this population of heavily pre-treated and refractory lymphoma patients, including in those with prior CD19 CAR T cell therapy, is very promising, Neelapu said. These results suggest the potential for off-the-shelf gamma delta CAR T cell therapy to be an effective treatment possibility for patients with B-cell lymphoma.

While autologous CD19-targeted CAR T cell therapy has been effective in R/R large B-cell lymphoma, there remains a need for alternative cell-based therapies. This study uses a subset of T cells, known as gamma delta 1 T cells, isolated from the peripheral blood of donors as the basis for CAR T cell therapy.

Gamma delta 1 T cells are desirable because they are able to combine both innate and adaptive mechanisms to recognize and kill malignant cells, and high levels of these cells in hematologic and solid tumors are associated with improved clinical outcomes. ADI-001 expresses major histocompatibility complex (MHC)-independent gamma delta T cell receptors, therefore lowering the risk of graft versus host disease (GvHD) without the need for gene editing.

The median age on the study was 62 years, and patients had received a median of 4 prior therapies. The treatment was well tolerated with most related events being grade 1 or 2. There were two cases of cytokine release syndrome and one case of immune effector cell-associated neurotoxicity syndrome. There were no reported cases of GvHD or dose-limiting toxicity.

Enrollment in the trial is ongoing and a potentially pivotal program is planned.

The study was funded by Adicet Bio, Inc. Neelapu has received research support and has served on the advisory board and as a consultant for Adicet Bio and has intellectual property related to cell therapy. A complete list of collaborating authors can be found within the abstract here.

Expanded NK cells combined with chemoimmunotherapy achieved durable responses in multiple myeloma (Abstract 8009)Results from the expansion phase of a Phase II clinical trial demonstrated that umbilical cord blood-derived expanded natural killer (NK) cells combined with chemotherapy and immunotherapies achieved durable responses in patients with multiple myeloma. Results from the completed clinical trial were presented by Samer Srour M.D., assistant professor of Stem Cell Transplantation & Cellular Therapy.

Thirty patients on the trial received NK cells plus elotuzumab (an immunotherapy monoclonal antibody), lenalidomide (an immunomodulatory drug) and high-dose melphalan chemotherapy before autologous stem cell transplant (ASCT).

At three months post-transplant, 97% of patients achieved at least a very good partial response (VGPR), including 76% with a complete response or stringent complete response, while 75% were minimal residual disease (MRD)-negative. At a median follow-up of 26 months, only four patients had progressed. At two years, the progression-free survival rate was 83% and the overall survival rate was 97%.

Patients with high-risk multiple myeloma have more options to treat their disease than previous years, but they continue to have poor outcomes, Srour said. These results indicate excellent hematologic and minimal residual disease responses and improved survival for these patients, suggesting this approach could provide an additional treatment opportunity.

NK cells are white blood cells that monitor the body for virus-infected and cancerous cells. MD Anderson researchers pioneered the approach to isolate and expand NK cells from umbilical cord blood to be used as cellular therapies. Lenalidomide enhances NK cell function and antibody-mediated cell toxicity against tumor targets. Preclinical data showed that lab-expanded NK cells demonstrated higher elotuzumab-mediated cytotoxicity against myeloma targets than non-expanded cells, and that the addition of elotuzumab to lenalidomide amplified the cord blood-NK cell antibody-dependent cellular cytotoxicity against a commonly used cell line to evaluate novel therapies for multiple myeloma (MM1.S) targets.

The study enrolled 30 patients with high-risk multiple myeloma, with a median age of 63. Twenty-nine patients (97%) had Revised Multiple Myeloma International Staging System (R-ISS) stages 2/3, 40% had 2 high-risk genetic abnormalities, and 23% had deletions or mutations of TP53. The primary endpoints were best response rate (VGPR) and MRD three months after ASCT.

Before the ASCT, stem cells are taken from the patient and stored. After treatment with the immunotherapy and chemotherapy drugs, stem cells are then returned to the patient to replace the blood-forming cells that were destroyed by the chemotherapy.

The treatment was well tolerated, with no unexpected serious adverse effects attributable to NK cells noted. The investigators plan to launch a randomized clinical trial to further explore this treatment combination for patients with high-risk multiple myeloma.

This study was supported with funding from the High-Risk Multiple Myeloma Moon Shot, part of MD Andersons Moon Shots Program, a collaborative effort to accelerate the development of scientific discoveries into clinical advances that save patients lives. The research also was supported by Celgene, a Bristol Myers Squibb company.

Srour has no conflicts of interest. A complete list of collaborating authors can be found within the abstract here.

Original post:
MD Anderson researchers present cellular therapy advances at the 2022 ASCO Annual Meeting - EurekAlert

TACSTD2 upregulation is an early reaction to lung infection | Scientific Reports – Nature.com

Lenrt, S. et al. Trop2: Jack of all trades, master of none. Cancers 12, 3328 (2020).

PubMed Central Google Scholar

Remk, J. et al. Trop-2 plasticity is controlled by epithelial-to-mesenchymal transition. Carcinogenesis 39, 14111418 (2018).

PubMed Google Scholar

Linnenbach, A. J. et al. Sequence investigation of the major gastrointestinal tumor-associated antigen gene family, GA733. Proc. Natl. Acad. Sci. U.S.A. 86, 2731 (1989).

ADS CAS PubMed PubMed Central Google Scholar

Linnenbach, A. J. et al. Retroposition in a family of carcinoma-associated antigen genes. Mol. Cell. Biol. 13, 15071515 (1993).

CAS PubMed PubMed Central Google Scholar

El Sewedy, T., Fornaro, M. & Alberti, S. Cloning of the murine TROP2 gene: Conservation of a PIP2-binding sequence in the cytoplasmic domain of TROP-2. Int. J. Cancer 75, 324330 (1998).

PubMed Google Scholar

Lipinski, M., Parks, D. R., Rouse, R. V. & Herzenberg, L. A. Human trophoblast cell-surface antigens defined by monoclonal antibodies. Proc. Natl. Acad. Sci. U.S.A. 78, 51475150 (1981).

ADS CAS PubMed PubMed Central Google Scholar

Stepan, L. P. et al. Expression of Trop2 cell surface glycoprotein in normal and tumor tissues. J. Histochem. Cytochem. 59, 701710 (2011).

CAS PubMed PubMed Central Google Scholar

Trerotola, M. et al. Upregulation of Trop-2 quantitatively stimulates human cancer growth. Oncogene 32, 222233 (2013).

CAS PubMed Google Scholar

Sozo, F., Wallace, M. J., Zahra, V. A., Filby, C. E. & Hooper, S. B. Gene expression profiling during increased fetal lung expansion identifies genes likely to regulate development of the distal airways. Physiol. Genomics 24, 105113 (2006).

CAS PubMed Google Scholar

McDougall, A. R. A. et al. The oncogene Trop2 regulates fetal lung cell proliferation. Am. J. Physiol. Lung Cell. Mol. Physiol. 301, 478489 (2011).

Google Scholar

Mustata, R. C. et al. Identification of Lgr5-independent spheroid-generating progenitors of the mouse fetal intestinal epithelium. Cell Rep. 5, 421432 (2013).

CAS PubMed Google Scholar

Fernandez Vallone, V. et al. Trop2 marks transient gastric fetal epithelium and adult regenerating cells after epithelial damage. Dev. Camb. Engl. 143, 14521463 (2016).

Google Scholar

Sun, W., Wilhelmina Aalders, T. & Oosterwijk, E. Identification of potential bladder progenitor cells in the trigone. Dev. Biol. 393, 8492 (2014).

CAS PubMed Google Scholar

Tsukahara, Y., Tanaka, M. & Miyajima, A. TROP2 expressed in the trunk of the ureteric duct regulates branching morphogenesis during kidney development. PLoS ONE 6, e28607 (2011).

ADS CAS PubMed PubMed Central Google Scholar

McDougall, A. R. A. et al. Intrauterine growth restriction alters the postnatal development of the rat cerebellum. Dev. Neurosci. 39, 215227 (2017).

CAS PubMed Google Scholar

Tsujikawa, M. et al. Identification of the gene responsible for gelatinous drop-like corneal dystrophy. Nat. Genet. 21, 420423 (1999).

CAS PubMed Google Scholar

Takaoka, M., Nakamura, T., Ban, Y. & Kinoshita, S. Phenotypic investigation of cell junction-related proteins in gelatinous drop-like corneal dystrophy. Investig. Ophthalmol. Vis. Sci. 48, 10951101 (2007).

Google Scholar

Aizarani, N. et al. A human liver cell atlas reveals heterogeneity and epithelial progenitors. Nature 572, 199204 (2019).

CAS PubMed PubMed Central Google Scholar

Goldstein, A. S. et al. Trop2 identifies a subpopulation of murine and human prostate basal cells with stem cell characteristics. Proc. Natl. Acad. Sci. U.S.A. 105, 2088220887 (2008).

ADS CAS PubMed PubMed Central Google Scholar

Okabe, M. et al. Potential hepatic stem cells reside in EpCAM+ cells of normal and injured mouse liver. Development 136, 19511960 (2009).

CAS PubMed Google Scholar

Yang, J. et al. Trop2 regulates the proliferation and differentiation of murine compact-bone derived MSCs. Int. J. Oncol. 43, 859867 (2013).

CAS PubMed Google Scholar

Memarzadeh, S. et al. Cell-autonomous activation of the PI3-kinase pathway initiates endometrial cancer from adult uterine epithelium. Proc. Natl. Acad. Sci. U.S.A. 107, 1729817303 (2010).

ADS CAS PubMed PubMed Central Google Scholar

Li, T. et al. Trop2 guarantees cardioprotective effects of cortical bone-derived stem cells on myocardial ischemia/reperfusion injury. Cell Transplant. 27, 12561268 (2018).

PubMed PubMed Central Google Scholar

Wang, J. et al. Loss of Trop2 promotes carcinogenesis and features of epithelial to mesenchymal transition in squamous cell carcinoma. Mol. Cancer Res. 9, 16861695 (2011).

CAS PubMed PubMed Central Google Scholar

Dreyfuss, D. & Ricard, J.-D. Acute lung injury and bacterial infection. Clin. Chest Med. 26, 105112 (2005).

PubMed Google Scholar

GBD 2017 Causes of Death Collaborators. Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 19802017: A systematic analysis for the Global Burden of Disease Study 2017. Lancet Lond. Engl. 392, 17361788 (2018).

Google Scholar

Osuka, A., Ogura, H., Ueyama, M., Shimazu, T. & Lederer, J. A. Immune response to traumatic injury: Harmony and discordance of immune system homeostasis. Acute Med. Surg. 1, 6369 (2014).

PubMed PubMed Central Google Scholar

Stoecklein, V. M., Osuka, A. & Lederer, J. A. Trauma equals dangerdamage control by the immune system. J. Leukoc. Biol. 92, 539551 (2012).

CAS PubMed PubMed Central Google Scholar

Huber-Lang, M., Lambris, J. D. & Ward, P. A. Innate immune responses to trauma. Nat. Immunol. 19, 327341 (2018).

CAS PubMed PubMed Central Google Scholar

Vieira Braga, F. A. et al. A cellular census of human lungs identifies novel cell states in health and in asthma. Nat. Med. 25, 11531163 (2019).

CAS PubMed Google Scholar

Travaglini, K. J. et al. A molecular cell atlas of the human lung from single-cell RNA sequencing. Nature 587, 619625 (2020).

ADS CAS PubMed PubMed Central Google Scholar

Yu, Y. et al. A rat RNA-Seq transcriptomic BodyMap across 11 organs and 4 developmental stages. Nat. Commun. 5, 3230 (2014).

ADS PubMed Google Scholar

Angelidis, I. et al. An atlas of the aging lung mapped by single cell transcriptomics and deep tissue proteomics. Nat. Commun. 10, 963 (2019).

ADS PubMed PubMed Central Google Scholar

Kim, E. Y. et al. Persistent activation of an innate immune axis translates respiratory viral infection into chronic lung disease. Nat. Med. 14, 633640 (2008).

CAS PubMed PubMed Central Google Scholar

Liu, Q. et al. Increased expression of TROP2 in airway basal cells potentially contributes to airway remodeling in chronic obstructive pulmonary disease. Respir. Res. 17, 159 (2016).

PubMed PubMed Central Google Scholar

Major, J. et al. Type I and III interferons disrupt lung epithelial repair during recovery from viral infection. Science 369, 712717 (2020).

ADS CAS PubMed PubMed Central Google Scholar

Kamata, H. et al. Epithelial cell-derived secreted and transmembrane 1A signals to activated neutrophils during Pneumococcal pneumonia. Am. J. Respir. Cell Mol. Biol. 55, 407418 (2016).

CAS PubMed PubMed Central Google Scholar

Katsura, H. et al. Human lung stem cell-based alveolospheres provide insights into SARS-CoV-2-mediated interferon responses and pneumocyte dysfunction. Cell Stem Cell 27, 890-904.e8 (2020).

CAS PubMed PubMed Central Google Scholar

Gerlach, R. L., Camp, J. V., Chu, Y.-K. & Jonsson, C. B. Early host responses of seasonal and pandemic influenza A viruses in primary well-differentiated human lung epithelial cells. PLoS ONE 8, e78912 (2013).

ADS PubMed PubMed Central Google Scholar

Shen, B. Q., Finkbeiner, W. E., Wine, J. J., Mrsny, R. J. & Widdicombe, J. H. Calu-3: A human airway epithelial cell line that shows cAMP-dependent Cl-secretion. Am. J. Physiol. 266, L493-501 (1994).

CAS PubMed Google Scholar

Rezaee, F. & Georas, S. N. Breaking barriers. New insights into airway epithelial barrier function in health and disease. Am. J. Respir. Cell Mol. Biol. 50, 857869 (2014).

PubMed PubMed Central Google Scholar

Soong, G., Parker, D., Magargee, M. & Prince, A. S. The type III toxins of Pseudomonas aeruginosa disrupt epithelial barrier function. J. Bacteriol. 190, 28142821 (2008).

CAS PubMed Google Scholar

Short, K. R. et al. Influenza virus damages the alveolar barrier by disrupting epithelial cell tight junctions. Eur. Respir. J. 47, 954966 (2016).

CAS PubMed Google Scholar

Linfield, D. T., Raduka, A., Aghapour, M. & Rezaee, F. Airway tight junctions as targets of viral infections. Tissue Barriers 9, 1883965 (2021).

PubMed PubMed Central Google Scholar

Nakatsukasa, M. et al. Tumor-associated calcium signal transducer 2 is required for the proper subcellular localization of claudin 1 and 7: Implications in the pathogenesis of gelatinous drop-like corneal dystrophy. Am. J. Pathol. 177, 13441355 (2010).

CAS PubMed PubMed Central Google Scholar

Xu, P. et al. A new in vitro model of GDLD by knocking out TACSTD2 and its paralogous gene EpCAM in human corneal epithelial cells. Transl. Vis. Sci. Technol. 7, 30 (2018).

CAS PubMed PubMed Central Google Scholar

Nakato, G. et al. Amelioration of congenital tufting enteropathy in EpCAM (TROP1)-deficient mice via heterotopic expression of TROP2 in Intestinal EPITHELIAL cells. Cells 9, 1847 (2020).

CAS PubMed Central Google Scholar

Singh, R. et al. A new triglycyl peptide linker for antibody-drug conjugates (ADCs) with improved targeted killing of cancer cells. Mol. Cancer Ther. 15, 13111320 (2016).

CAS PubMed Google Scholar

Szala, S. et al. Molecular cloning of cDNA for the carcinoma-associated antigen GA733-2. Proc. Natl. Acad. Sci. 87, 35423546 (1990).

ADS CAS PubMed PubMed Central Google Scholar

Mashhadi, S. M. Y. et al. Shedding light on the EpCAM: An overview. J. Cell. Physiol. 234, 1256912580 (2019).

Google Scholar

Here is the original post:
TACSTD2 upregulation is an early reaction to lung infection | Scientific Reports - Nature.com

‘Unnatural selection’: How humans are altering the evolution of other animals – Genetic Literacy Project

The bouncing orange specks could be popcorn dancing on a hot plate. But theres something odd about how they move. Individual kernels spin in tight circles. Pairs slow dance a pas de deux. A cluster performs one full rotation counter-clockwise before dispersing. Each collision sets off a new motion. They seem to bebehaving.

What look like popcorn kernels inthis short videoare in fact a swarm of microscopic xenobots: tiny living robots, assembled from frog cells.

While living robots might seem a strange concept, in fact the first robots were made of flesh, not metal. Theword was coined in 1921, in a play by Czech playwright Karel apek.Rossums Universal Robotswas a thought experiment along the lines of Mary Shelleys Frankenstein, about a scientists desire to create artificial people. Nature has found only one method of organising living matter, declares Rossum, the scientist in question. There is, however, another method, more simple, flexible and rapid which has not yet occurred to nature at all.

Imagine him sitting over a test tube and thinking how the whole tree of life would grow from him, says another character.

In the century that followed, however, robots developed as things of steel and wire, rather than living tissue. Engineering moved faster than biology, says Douglas Blackiston, a developmental biologist at Tufts University. But biology is rapidly catching up. Blackiston is one of a team of scientists designing xenobots: tiny living robots, painstakingly constructed from tissue harvested fromXenopus laevis, the African clawed frog.

Thefirst xenobotswere revealed to the world at the start of 2020: minuscule cubes formed of skin cells and propelled by two stubby legs made of heart muscle. They were designed by a computer algorithm and hand-built by researchers with the objective to make the xenobots walk. (In a pleasing coincidenceXenopus means strange foot.) These organic automatons could also work together to move particles around their environment, and unlike mechanical robots they self-healed when injured.

Read more here:
'Unnatural selection': How humans are altering the evolution of other animals - Genetic Literacy Project

Lasers, Fish-Skin Bandages and Pain-Free Vaccines: The Winners of Our 3rd Annual STEM Writing Contest – The New York Times

Saahil Joshi, age 17, Crystal Springs Uplands School, Hillsborough, Calif.: Too Many Cooks Spoil the Broth: The Science and Future of Drug-Drug Interactions

Micah: Salt: The Sapid and Sophisticated Seasoning

Katherine Kricorian, age 17, Santa Susana High School, Simi Valley, Calif.: From Algae to Energy: A Blooming Solution to Pollution

Chloe Lee, age 14, Korea International School Pangyo Campus, Gyeonggi-do, Korea: Do Plants Have Feelings?

Seungjae (Andy) Lee, age 13, Hong Kong International School, Tai Tam, Hong Kong: Keeping Your Pet Friend Forever: Is Cloning a Soul Possible?

Zhuocheng Li, age 16, Green Hope High School, Cary, N.C.: The Blood That Saved Countless Lives

Andrew C. Lin, age 12, Visions in Education Homeschool Academy, Carmichael, Calif.: Breaking the Speech Barrier

Andy Lu, age 16, Desert Vista High School, Phoenix: Hypersonic Flight: Can We Go Faster?

Camille: Sugar and the Body: A Bittersweet Relationship

Natalia Meza, age 17, American School of Madrid, Madrid: What Happens in Vagus, Stays in Vagus?

Aman Mistry, age 17, Smithtown High School, East Saint James, N.Y.: Helping a Blind Man See: The Miracle of Optogenetics

See the rest here:
Lasers, Fish-Skin Bandages and Pain-Free Vaccines: The Winners of Our 3rd Annual STEM Writing Contest - The New York Times

Autolus Therapeutics to Present Four Clinical Data Updates at the European Hematology Association Congress – GlobeNewswire

- AUTO4: oral presentation on initial clinical experience in peripheral T cell lymphoma- AUTO1/22: oral presentation on initial experience in r/r pediatric B-cell acute lymphoblastic leukemia- obe-cel: poster presentation in r/r primary CNS lymphoma- obe-cel: poster presentation in r/r B-non-Hodgkins lymphoma and chronic lymphoblastic leukemia- Conference call to be held on June 13, 2022 at 7:30 am EST/12:30 pm BST

LONDON, May 12, 2022 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc(Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announces the online publication of four abstracts submitted to the European Hematology Association (EHA) Congress to be held June 9-12, 2022. Autolus plans to present more detail on these programs and the next steps in a conference call following the EHA presentations, on June 13, 2022, details below.

We are delighted to be presenting encouraging early clinical data from four of our pipeline programs, including important additive safety and efficacy data from our lead asset obe-cel in indications beyond adult r/r B-ALL. These data demonstrate the inherent value in both our pipeline and our technology base from which it originates, said Dr. Christian Itin, Chief Executive Officer of Autolus. With oral presentations on the early safety, tolerability, feasibility and preliminary efficacy of AUTO4 and AUTO1/22, were in a great place to evaluate the next strategic steps for these candidates and further build on the data presented here.

Abstracts to be presented:

Conference Call

Management will host a conference call and webcast on June 13, 2022 at7:30 am ET/12:30 pm BST to discuss the EHA data. To listen to the webcast and view the accompanying slide presentation, please go to the events section of Autolus website.

The call may also be accessed by dialing (866) 679-5407 for U.S. and Canada callers or (409) 217-8320 for international callers. Please reference conference ID: 6594553. After the conference call, a replay will be available for one week. To access the replay, please dial (855) 859-2056 for U.S. and Canada callers or (404) 537-3406 for international callers. Please reference conference ID: 6594553.

About Autolus Therapeutics plcAutolus is a clinical-stage biopharmaceutical company developing next-generation, programmed T cell therapies for the treatment of cancer. Using a broad suite of proprietary and modular T cell programming technologies, the Company is engineering precisely targeted, controlled and highly active T cell therapies that are designed to better recognize cancer cells, break down their defense mechanisms and eliminate these cells. Autolus has a pipeline of product candidates in development for the treatment of hematological malignancies and solid tumors. For more information, please visit http://www.autolus.com.

About obe-cel(AUTO1)Obe-cel is a CD19 CAR T cell investigational therapy designed to overcome the limitations in clinical activity and safety compared to current CD19 CAR T cell therapies.Designed to have a fast target binding off-rate to minimize excessive activation of the programmed T cells, obe-cel may reduce toxicity and be less prone to T cell exhaustion, which could enhance persistence and improve the ability of the programmed T cells to engage in serial killing of target cancer cells. In collaboration with Autolus academic partner, UCL, obe-cel is currently being evaluated in a Phase 1 clinical trials for B-NHL. Autolus has progressed obe-cel to the FELIX trial, a potential pivotal trial for adult ALL.

About obe-cel FELIX clinical trialAutolus Phase 1b/2 clinical trial of obe-cel is enrolling adult patients with relapsed / refractory B-precursor ALL. The trial had a Phase 1b component prior to proceeding to the single arm, Phase 2 clinical trial. The primary endpoint is overall response rate, and the secondary endpoints include duration of response, MRD negative CR rate and safety. The trial is designed to enroll approximately 100 patients across 30 of the leading academic and non-academic centers in the United States,United KingdomandEurope. [NCT04404660]

About AUTO1/22AUTO1/22 is a novel dual targeting CAR T cell based therapy candidate based on obe-cel. It is designed to combine the enhanced safety, robust expansion & persistence seen with the fast off rate CD19 CAR from obe-cel with a high sensitivity CD22 CAR to reduce antigen negative relapses. This product candidate is currently in a Phase 1 clinical trial called CARPALL for patients with r/r pediatric ALL. [NCT02443831]

About AUTO4AUTO4 is a programmed T cell product candidate in clinical development for T cell lymphoma, a setting where there are currently no approved programmed T cell therapies. AUTO4 is specifically designed to target TRBC1 derived cancers, which account for approximately 40% of T cell lymphomas, and is a complement to the AUTO5 T cell product candidate, which is in pre-clinical development. AUTO4 has been tested in a Phase 1 clinical trial, LibRA1 for patients with peripheral T cell Lymphoma.

Forward-Looking StatementsThis press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are statements that are not historical facts, and in some cases can be identified by terms such as "may," "will," "could," "expects," "plans," "anticipates," and "believes." These statements include, but are not limited to, statements regarding Autolus development of the obe-cel program; the future clinical development, efficacy, safety and therapeutic potential of its product candidates, including progress, expectations as to the reporting of data, conduct and timing and potential future clinical activity and milestones; expectations regarding the initiation, design and reporting of data from clinical trials; expectations regarding regulatory approval process for any product candidates; the collaboration between Autolus and Blackstone; the discovery, development and potential commercialization of potential product candidates including obe-cel using Autolus technology and under the collaboration agreement; the therapeutic potential for Autolus in next generation product developments of obe-cel in B-cell malignancies; the potential and timing to receive milestone payments and pay royalties under the strategic collaboration; and the Companys anticipated cash runway. Any forward-looking statements are based on management's current views and assumptions and involve risks and uncertainties that could cause actual results, performance, or events to differ materially from those expressed or implied in such statements. These risks and uncertainties include, but are not limited to, the risks that Autolus preclinical or clinical programs do not advance or result in approved products on a timely or cost effective basis or at all; the results of early clinical trials are not always being predictive of future results; the cost, timing and results of clinical trials; that many product candidates do not become approved drugs on a timely or cost effective basis or at all; the ability to enroll patients in clinical trials; possible safety and efficacy concerns; and the impact of the ongoing COVID-19 pandemic on Autolus business. For a discussion of other risks and uncertainties, and other important factors, any of which could cause Autolus actual results to differ from those contained in the forward-looking statements, see the section titled "Risk Factors" in Autolus' Annual Report on Form 20-F filed with the Securities and Exchange Commission on March 10, 2022, as well as discussions of potential risks, uncertainties, and other important factors in Autolus' subsequent filings with the Securities and Exchange Commission. All information in this press release is as of the date of the release, and Autolus undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise, except as required by law.

Contact:

Olivia Manser+44 (0) 7780 471568o.manser@autolus.com

Julia Wilson+44 (0) 7818 430877j.wilson@autolus.com

Susan A. NoonanS.A. Noonan Communications+1-917-513-5303susan@sanoonan.com

More:
Autolus Therapeutics to Present Four Clinical Data Updates at the European Hematology Association Congress - GlobeNewswire

Autolus Therapeutics to Present Four Clinical Data Updates at the European Hematology Association Congress – Yahoo Finance

Autolus Limited

- AUTO4: oral presentation on initial clinical experience in peripheral T cell lymphoma- AUTO1/22: oral presentation on initial experience in r/r pediatric B-cell acute lymphoblastic leukemia- obe-cel: poster presentation in r/r primary CNS lymphoma- obe-cel: poster presentation in r/r B-non-Hodgkins lymphoma and chronic lymphoblastic leukemia- Conference call to be held on June 13, 2022 at 7:30 am EST/12:30 pm BST

LONDON, May 12, 2022 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announces the online publication of four abstracts submitted to the European Hematology Association (EHA) Congress to be held June 9-12, 2022. Autolus plans to present more detail on these programs and the next steps in a conference call following the EHA presentations, on June 13, 2022, details below.

We are delighted to be presenting encouraging early clinical data from four of our pipeline programs, including important additive safety and efficacy data from our lead asset obe-cel in indications beyond adult r/r B-ALL. These data demonstrate the inherent value in both our pipeline and our technology base from which it originates, said Dr. Christian Itin, Chief Executive Officer of Autolus. With oral presentations on the early safety, tolerability, feasibility and preliminary efficacy of AUTO4 and AUTO1/22, were in a great place to evaluate the next strategic steps for these candidates and further build on the data presented here.

Abstracts to be presented:

Title: Safety and preliminary efficacy findings of AUTO4, a TRBC1-targetting CAR, in relapsed/refractory TRBC1 positive selected T Cell Non-Hodgkin Lymphoma LINKSession Title: Gene therapy and cellular immunotherapy - Clinical 2Session date and time: Saturday, June 11 - 16:30 - 17:45 CESTSession room: Hall Strauss 1-2Final Abstract Code: S261Presenting Author: Kate CwynarskiSummary: Peripheral T cell lymphomas (PTCL) are typically aggressive, treatment resistant, and associated with poor prognosis. Finding the right target is challenging because there is a lack of tumor-specific antigens, and pan-T cell depletion leads to immunosuppression. T cell lymphoma is clonal, and tumor cells express either TRBC1 or TRBC2. AUTO4 targets TRBC1+ cells, which allows part of the T cell compartment to be retained. As of 9 February 2022, 9 patients screened for r/r TRBC1+ peripheral T-cell lymphoma have been treated with AUTO4. Two patients had prior stem cell transplantation. After lymphodepletion with Flu/Cy, 3 patients received 25 x 106 CAR T cells, 2 patients received 75 x 106 CAR T cells, 1 patient received 225 x 106 CAR T cells and 3 patients received 450 x 106 CAR T cells. AUTO4 demonstrated a tolerable safety profile, with no patient experiencing any dose limiting toxicities, and no neurotoxicity/immune effector cell-associated neurotoxicity (ICANS). Three patients experienced cytokine release syndrome (CRS) (1 patient with Grade 1, 1 patient with Grade 2 and 1 patient with Grade 3). Of the 9 patients treated, 5 patients had achieved complete metabolic responses (CMR) by PET-CT at Month 1, 1 patient remains with a partial response (PR) 6 months post AUTO4 infusion, and 3 patients did not respond. All 3 patients at the highest dose level achieved a CMR at Month 1.

Title: Dual antigen targeting with co-transduced CD19/22 CAR T cells for relapsed/refractory ALL (AUTO1/22) LINKSession Title: Gene therapy and cellular immunotherapy - Clinical 1Session date and time: Saturday, June 11 - 11:30 - 12:45 CESTSession room: Hall Strauss 1-2Final Abstract Code: S259Presenting Author: Sara GhorashianSummary: CD19 negative escape is a major cause of relapse after CD19 CAR T cell therapy for relapsed/refractory (r/r) pediatric ALL. To overcome this challenge, AUTO1/22 builds on the favorable safety profile and excellent persistence of obe-cel by combining it with an additional CD22 targeting CAR. As of 8 February 2022, 10 pediatric ALL patients have been treated with AUTO1/22 and 8 are evaluable with >1 month follow-up. 5 of 8 patients had relapsed post allogeneic stem cell transplant (SCT), 4 had received prior Blincyto and 3 had relapsed after prior Kymriah. CRS occurred in 7/8 patients (grade 1 n=2, grade 2 n=5), but severe CRS was not seen. 7 of 8 evaluable patients achieved MRD negative complete response (CR) at 1 month post infusion. Overall, at a median follow up of 4.8 months, 5/8 patients remain in MRD negative CR at last follow up. The study results demonstrate that dual CD19/22 targeting CAR T cells generated by co-transduction show an acceptable safety profile, with robust expansion/persistence and early efficacy in a heavily pre-treated cohort. To date with limited follow-up we have not observed antigen negative relapse but longer follow up is needed.

Title: Safety and efficacy findings of AUTO1, a fast off-rate CD19 CAR, in relapsed/refractory Primary CNS Lymphoma LINKSession Title: Poster sessionSession date and time: Friday, June 10 - 16:30 - 17:45 CESTFinal Abstract Code: P1460Presenting Author: Claire RoddieSummary: Relapsed/refractory primary central nervous system lymphoma (PCNSL) has a median overall survival of 2-8 months and few therapeutic options. obe-cel (AUTO1) has previously demonstrated high remission rates, low incidence of CRS/ICANS and long-term persistence, making it a viable treatment option for PCNSL. As of 14 February 2022, the CAROUSEL study enrolled 6 patients with r/r PCNSL where the median prior lines of treatment was 2. 5 patients were infused with IV AUTO1 and 1 patient with intraventricular AUTO1. Following CAR T infusion, Grade 1 and 2 CRS affected 1 and 3 patients respectively and any Grade ICANS was observed in 2 patients with 2 Grade 3 events. AUTO1 engraftment and response was evaluable in 4 patients at 1 month following iv infusion. 2 of 4 patients had no measurable disease at 2 and 6 months of follow up respectively. AUTO1 showed encouraging remission rates and excellent CAR T engraftment/expansion in the blood and CSF. Intraventricular administration was well-tolerated and showed that AUTO1 has activity via that route in a patient who failed IV therapy. Additional patients updated biological data and longer follow up will be presented.

Title: Safety and efficacy findings of AUTO1, a fast off-rate CD19 CAR, in relapsed/refractory B-Cell Non-Hodgkins Lymphoma (B-NHL), and chronic Lymphocytic Leukemia (CLL) / Small Lymphocytic Lymphoma (SLL) LINKSession Title: Poster sessionSession date and time: Friday, June 10 - 16:30 - 17:45 CESTFinal Abstract Code: P1459Presenting Author: Claire Roddie Summary: obe-cel (AUTO1) has demonstrated an excellent safety profile in previous trials, with low levels of CRS/ICANS and long-term engraftment of CAR T cells, making it an ideal CAR T candidate to evaluate in B-NHL, CLL/SLL. As of 8 February 2022, 19 patients had been infused with AUTO1; 10 with low grade NHL, 6 with DLBCL and 3 with CLL. Patients treated had received a median of 3 prior lines of treatment. Grade 1 CRS was reported in 6/19 and Grade 2 CRS in 3/19. No ICANS was observed in the B-NHL and CLL cohorts. In the lg-NHL and DCBCL cohorts, 10/10 and 4/5 evaluable patients respectively were in CMR post-treatment. Responses were ongoing in 9/10 lg-NHL at 12 months and in 4/4 DLBCL at months 1,3,3 and 6. In the CLL cohort, 2/3 evaluable patients achieved MRD negative remission in the bone marrow with residual small volume lymph nodes by CT at 6 and 3 months of follow up respectively. AUTO1 demonstrated a tolerable safety profile in patients with r/r B-NHL and CLL despite high disease burden. Early data shows excellent complete remission rates and CAR engraftment/expansion. Additional patients, updated data and longer follow up will be presented.

Story continues

Conference Call

Management will host a conference call and webcast on June 13, 2022 at 7:30 am ET/12:30 pm BST to discuss the EHA data. To listen to the webcast and view the accompanying slide presentation, please go to the events section of Autolus website.

The call may also be accessed by dialing (866) 679-5407 for U.S. and Canada callers or (409) 217-8320 for international callers. Please reference conference ID: 6594553. After the conference call, a replay will be available for one week. To access the replay, please dial (855) 859-2056 for U.S. and Canada callers or (404) 537-3406 for international callers. Please reference conference ID: 6594553.

About Autolus Therapeutics plcAutolus is a clinical-stage biopharmaceutical company developing next-generation, programmed T cell therapies for the treatment of cancer. Using a broad suite of proprietary and modular T cell programming technologies, the Company is engineering precisely targeted, controlled and highly active T cell therapies that are designed to better recognize cancer cells, break down their defense mechanisms and eliminate these cells. Autolus has a pipeline of product candidates in development for the treatment of hematological malignancies and solid tumors. For more information, please visit http://www.autolus.com.

About obe-cel (AUTO1)Obe-cel is a CD19 CAR T cell investigational therapy designed to overcome the limitations in clinical activity and safety compared to current CD19 CAR T cell therapies. Designed to have a fast target binding off-rate to minimize excessive activation of the programmed T cells, obe-cel may reduce toxicity and be less prone to T cell exhaustion, which could enhance persistence and improve the ability of the programmed T cells to engage in serial killing of target cancer cells. In collaboration with Autolus academic partner, UCL, obe-cel is currently being evaluated in a Phase 1 clinical trials for B-NHL. Autolus has progressed obe-cel to the FELIX trial, a potential pivotal trial for adult ALL.

About obe-cel FELIX clinical trialAutolus Phase 1b/2 clinical trial of obe-cel is enrolling adult patients with relapsed / refractory B-precursor ALL. The trial had a Phase 1b component prior to proceeding to the single arm, Phase 2 clinical trial. The primary endpoint is overall response rate, and the secondary endpoints include duration of response, MRD negative CR rate and safety. The trial is designed to enroll approximately 100 patients across 30 of the leading academic and non-academic centers in the United States, United Kingdom and Europe. [NCT04404660]

About AUTO1/22AUTO1/22 is a novel dual targeting CAR T cell based therapy candidate based on obe-cel. It is designed to combine the enhanced safety, robust expansion & persistence seen with the fast off rate CD19 CAR from obe-cel with a high sensitivity CD22 CAR to reduce antigen negative relapses. This product candidate is currently in a Phase 1 clinical trial called CARPALL for patients with r/r pediatric ALL. [NCT02443831]

About AUTO4AUTO4 is a programmed T cell product candidate in clinical development for T cell lymphoma, a setting where there are currently no approved programmed T cell therapies. AUTO4 is specifically designed to target TRBC1 derived cancers, which account for approximately 40% of T cell lymphomas, and is a complement to the AUTO5 T cell product candidate, which is in pre-clinical development. AUTO4 has been tested in a Phase 1 clinical trial, LibRA1 for patients with peripheral T cell Lymphoma.

Forward-Looking StatementsThis press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are statements that are not historical facts, and in some cases can be identified by terms such as "may," "will," "could," "expects," "plans," "anticipates," and "believes." These statements include, but are not limited to, statements regarding Autolus development of the obe-cel program; the future clinical development, efficacy, safety and therapeutic potential of its product candidates, including progress, expectations as to the reporting of data, conduct and timing and potential future clinical activity and milestones; expectations regarding the initiation, design and reporting of data from clinical trials; expectations regarding regulatory approval process for any product candidates; the collaboration between Autolus and Blackstone; the discovery, development and potential commercialization of potential product candidates including obe-cel using Autolus technology and under the collaboration agreement; the therapeutic potential for Autolus in next generation product developments of obe-cel in B-cell malignancies; the potential and timing to receive milestone payments and pay royalties under the strategic collaboration; and the Companys anticipated cash runway. Any forward-looking statements are based on management's current views and assumptions and involve risks and uncertainties that could cause actual results, performance, or events to differ materially from those expressed or implied in such statements. These risks and uncertainties include, but are not limited to, the risks that Autolus preclinical or clinical programs do not advance or result in approved products on a timely or cost effective basis or at all; the results of early clinical trials are not always being predictive of future results; the cost, timing and results of clinical trials; that many product candidates do not become approved drugs on a timely or cost effective basis or at all; the ability to enroll patients in clinical trials; possible safety and efficacy concerns; and the impact of the ongoing COVID-19 pandemic on Autolus business. For a discussion of other risks and uncertainties, and other important factors, any of which could cause Autolus actual results to differ from those contained in the forward-looking statements, see the section titled "Risk Factors" in Autolus' Annual Report on Form 20-F filed with the Securities and Exchange Commission on March 10, 2022, as well as discussions of potential risks, uncertainties, and other important factors in Autolus' subsequent filings with the Securities and Exchange Commission. All information in this press release is as of the date of the release, and Autolus undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise, except as required by law.

Contact:

Olivia Manser+44 (0) 7780 471568o.manser@autolus.com

Julia Wilson+44 (0) 7818 430877j.wilson@autolus.com

Susan A. NoonanS.A. Noonan Communications+1-917-513-5303susan@sanoonan.com

Originally posted here:
Autolus Therapeutics to Present Four Clinical Data Updates at the European Hematology Association Congress - Yahoo Finance

Google Reverses Ban on Ads for All Stem Cell Therapies, Will Allow FDA-Approved Ones – Gizmodo

Photo: Scott Strazzante/San Francisco Chronicle (AP)

Google announced Monday it will allow ads for stem cell treatments approved by the Food and Drug Administration to appear in search results starting in July. The tech giant previously banned any ads for stem cell therapies, FDA-approved or otherwise.

In an update to its policies page first spotted by Gizmodo, the company said that, starting July 11, it will permit search engine ads for stem cell therapies given the thumbs up from the FDA, a very small list of just 23 companies that treat some blood disorders and cancers, according to the FDAs website.

At the same time, Google is clarifying its policy language on stem cell therapy ads, which would allow a global cell or gene therapy company to advertise if the ads are are exclusively educational or informational in nature, regardless of regulatory approval status. Google did not clarify what would constitute educational or informational, nor did the company respond to a request for comment how it will restrict less-than-reputable products from being advertised with its technology going forward. We will update the story if we hear more.

The search engine said it banned all advertising for stem cell treatments back in 2019, proclaiming at the time it was restricting ads that have no established biomedical or scientific basis. In 2021, the company clarified that it was restricting ads for experimental treatments meant for so-called biohacking or other DIY genetic engineering, as well as any cell or gene therapies like stem cell therapy.

Despite the pledge to ban such ads or Mondays announced change, a simple Google search reveals just how easily bad actors can get around the restrictions. Searching for stem cells for neuropathy reveals several misleading ad results for stem cell treatments that are not FDA approved, though at least one maker claims it is FDA registered and another says its treatment is supported by FDA master files.

G/O Media may get a commission

Save $70

Apple AirPods Max

Experience Next-Level SoundSpatial audio with dynamic head tracking provides theater-like sound that surrounds you

Paul Knoepfler, a professor at the University of California Davis School of Medicine who researches stem cells and cancer, has written before about Googles problematic search engine ad policies that allow stem cell companies to easily advertise their products in spite of the tech giants rules. In an email, he told Gizmodo he is concerned How effectively the new rule for strictly educational ads would be maintained, particularly given the context of Google Search now so often highly ranking promotional clinic websites arguably presented as educational material.

Stem cells as an industry have grown rapidly in recent years and are expected to continue doing so, with MarketWatch reporting in February the $2.75 billion industry is expected to more than double to $5.72 billion by 2028.

Stem cell treatments are approved by the FDAs Cellular, Tissue and Gene Therapies Advisory Committee. Though some companies claim in advertising they have FDA approval, being listed on clinicaltrials.gov database or being registered with the FDA isnt full-on approval, according to the agencys guidelines. The fact that companies regularly run around Googles existing policies leaves even more questions on the table. Knoepfler asked whether clinical trial recruitment be allowed, when hes often seen such trials already claiming their treatment already works.

Perhaps good citizens in the regenerative medicine world want the opportunity to run such ads related to clinical trial recruitment, but even exclusively educational ads of that type with good intentions could run into ethical issues, Knoepfler added.

Shoshana Wodinsky contributed reporting.

Visit link:
Google Reverses Ban on Ads for All Stem Cell Therapies, Will Allow FDA-Approved Ones - Gizmodo

The Stroller, May 9, 2022: Events in the Alle-Kiski Valley – TribLIVE

Publicize your community events, fundraisers and club meetings for free in The Stroller. Send information at least a week in advance to vndnews@triblive.com. Please include a daytime telephone number.

Planting day scheduled at Tarentum friendship garden

Volunteers are welcome to help at a summer garden day set for 10 a.m. to noon Saturday at the Greg Blythe Friendship Garden on First Avenue in Tarentum.

Bring tools and gloves.

Trivia night set at Lower Burrell VFW

Alle-Kiski Strong Chamber Trivia Night will begin at 6 p.m. May 19 in the Lower Burrell Veterans of Foreign Wars, Wildlife Lodge Road.

Teams will be made up of six to eight members. Cash prizes will be awarded to the top three teams. Cost is $20 per person and includes a pasta buffet. Sponsorship opportunities are available.

For registration or questions, call 724-224-3400 or email lynda@akstrong.com.

Participants welcome at NK-Arnold Memorial Day events

New Kensington-Arnold Joint Veterans will have wreath laying ceremonies on Memorial Day in the two cities.

Individuals and groups wishing to participate should call Greg Kurpakus at 724-467-7125 or Patsy Fraino at 724-337-3182.

Memorial Day events to be published

The Valley News Dispatch is compiling a list of Memorial Day observances to be published in the Valley News Dispatch and online at triblive.com.

If your organization or community is planning an event, please send the information in as soon as possible to: Carol Pinto-Smith, Valley News Dispatch, 210 Wood St., Tarentum, PA 15084; e-mail cpinto-smith@triblive.com or fax 724-226-4677.

Calendar

Apollo

Tuesday: Apollo Memorial Library will host a new summer reading book club for students who are 14 to 18 years old at 5 p.m. the second Tuesday of the month. Reservations required. Reservations: 724-478-4214 or apollo@armstronglibraries.org.

Wednesday: Apollo Hose Co. No. 2 will host bingo at 7 p.m. at the firehall, 325 N. Fourth St. Doors open at 5:30 p.m. Details: 724-478-4831.

Saturday: A vendor fair will be from 9 a.m. to 2 p.m. in the parish center at St. James Parish, 109 Owens View Ave. All vendors needed. Cost: $20 per table; without electricity, $15. Details: Linda, 724-882-8776.

May 17: The Graphic Novel Book Club for children age 10 to 14 at Apollo Memorial Library will meet at 5 p.m. the third Tuesday of each month at the library, 219 N. Pennsylvania Ave. Reservations required. Reservations: 724-478-1693.

Bethel

Tuesday: The Armstrong Nature Book Club will meet at 7 p.m. at the Outdoor Discovery Center at Crooked Creek, 142 Kerr Road. The selection will be, Entangled Life, by Merlin Sheldrake. Reservations and masks required. Reservations and details: armstrongcenter.org/odc-events.

May 23: The Knee High To Nature Series at the Outdoor Discovery Center at Crooked Creek will offer a free science program, Awesome Opossums, for children in elementary school at 6 p.m. May 23 at the center, 142 Kerr Road. Reservations required. Reservations: armstrongcenter.org/odc-events.

Brackenridge

Wednesday: Al-Anon will meet at 8 p.m. at Trinity United Methodist Church, 847 10th Ave. The group offers help and hope for families and friends of alcoholics.

Cheswick

Today: Springdale High School Alumni Association will meet at 7 p.m. in Cheswick Presbyterian Church, 1401 Pittsburgh St. Details: Mike, 724-275-7566.

Freeport

Wednesday: The Thrift Store Clothing Ministry at Freeport United Methodist Church, 211 Fourth St., will be open from noon to 3 p.m. Cash only. Donations of spring and summer clothing, shoes, bedding and purses welcome. Donations must be laundered and free from pet hair. Details: 724-295-3095.

Harrison

Tuesday: The Who Knew? program at Community Library of Allegheny Valley will present, Sensational Gardens of Pa., at 6 p.m. at the library and online at Zoom.us. Reservations required. Reservations: 724-226-3491 or visit the calendar tab at alleghenyvalleylibrary.org.

Wednesday: The PriorityCare program at Allegheny Valley Hospital will offer a free seminar, Say No To Stroke, at 1:30 p.m. in the Charles W. Young Conference Center at the hospital, 1301 Carlisle St., Natrona Heights. Reservations required. Reservations: 724-226-7339.

Wednesday: The Anime Club at Community Library of Allegheny County, 1522 Broadview Blvd., will meet at 5:30 p.m. at the library. Focused for adults, but teens and young adults welcome. Reservations required. Reservations: 724-226-3491 or visit the calendar section at AlleghenyValleyLibrary.org.

Wednesday: The Agape Thrift Shop at Grace United Methodist Church, 1333 Freeport Road, will be open from 1 to 4 p.m. Masks required. Clean spring and summer clothing in all sizes is needed. Bring donations on Wednesday or leave them on the front porch. Do not place donations in the blue bins behind the church.

Wednesday: Allegheny Valley Association of Churches Food Bank will be open to anyone in need from 1:30 to 5 p.m. at 1913 Freeport Road, Natrona Heights. Pull into the center parking lot and food will be placed into your vehicle. Those who are not yet registered should come from 2:30 to 4:30 p.m. Wednesday.

Thursday: The annual St. Joseph High School Latin Mass will be at 7 p.m. at Guardian Angels Parish Most Blessed Sacrament Church, Natrona Heights. Bishop Larry Kulick of the Catholic Diocese of Greensburg will be the celebrant. A reception will be afterward.

Thursday: Burtner House Restoration Society will meet at 6:30 p.m. in the Harrison Municipal Building, 1 Municipal Drive, Natrona Heights. New members welcome. Details: Jeff Jones, 724-205-8784 or BHRS1821@gmail.com.

Thursday : Community Library of Allegheny Valley will offer, Honeybees: The Perfect Pollinator, at 6 p.m. at the library, 1522 Broadview Blvd. The speaker will be Bill Kopar of Kopar Honey Farm. Reservations required. Reservations: alleghenyvalleylibrary.org.

May 18: Community Library of Allegheny Valley, 1522 Broadview Blvd. will offer a program, Gardening with Native Plants, at 5:30 p.m. at the library and online. Julie Travaglini of the Allegheny Land Trust will be the speaker. Reservations required. Reservations: alleghenyvalleylibrary.org.

May 21: Harrison Township Recreation board is seeking owners of commercial and non-commercial vehicles to participate in its third annual touch-a-truck event planned at Highlands High School, Natrona Heights. Details: Natalie Cale, 724-448-6588 or nmcajka@yahoo.com.

Jefferson

Tuesday: Saxonburg Goldenagers will meet at noon at the Veterans of Foreign Wars, Dinnerbell Road. Lunch will be served and entertainment will be afterward. New members welcome.

Kiski Township

May 21: Kiski Township Volunteer Fire Department will host a parking lot bingo at 5 p.m. at the firehall, 1037 Route 66. Gates open at 4 p.m. Cost: $15 per person, includes supplies. Only 125 spots available. Reservations: Morgan, 724-466-2812, or Megan, 724-575-2473.

Kittanning

Sundays and Thursdays Armstrong County Historical Museum, 330 N. McKean St., will be open from 1 to 3 p.m. Other hours available by appointment. Free parking available behind the museum via the North Grant Avenue entrance. Details: 724-548-5707 or achgs300@gmail.com.

Leechburg

Today: Leechburg Volunteer Fire Company will host bingo at 7 p.m. at the firehall, 268 Canal St. Doors open at 5 p.m. The kitchen will be open.

Today: Leechburg Public Library Board of Directors will meet at 6:30 p.m. at the library, 137 Market St. Public welcome.

Today: The Leechburg Area Museum and Historical Society, 118 First St., is closed and will reopen for summer on May 28. To arrange a private tour, email lamahs@windstream.net or call 724-845-8914 and leave a message.

Lower Burrell

Today: Alle-Kiski Multiple Sclerosis Support Group will meet at 7 p.m. in Faith Hall of Puckety Presbyterian Church, 1009 Puckety Church Road. Chiropractor Dr. Misty OToole will discuss stem cell therapies. New members welcome. Details: Mary, 724-337-7133, or Carol, 724-335-7136.

Saturday: Church of God is accepting space reservations for a parking lot treasures sale set for 8 a.m. to 2 p.m. at the church, 273 Chester Dr. Rain date: May 21. Reservations and details: 724-335-4422 or lbcog@hotmail.com.

Saturday: The annual Animal Protectors Hearts for Strays spring luncheon will be at 11:30 a.m. at Hill Crest Country Club. Doors open at 10 a.m. There will be a basket raffle, door prizes, card games and a 50/50 raffle. Cost: $30. Reservations: jlessig@animalprotectors.net or the events tab at animalprotectors.net.

May 28 to Oct. 8: The Lower Burrell Farmers Market is seeking vendors for the upcoming season. Markets are from 9 a.m. to 1 p.m. Saturdays at 2800 Bethel St. Setup begins at 8 a.m. Cost: $40 for the season and free electric is available. Merchandise must be home grown, homemade or hand crafted. Vendors must participate the whole season. Details: TimPamKey@yahoo.com.

Manor

Tuesday: An American Red Cross Blood community blood drive will be from 11 a.m. to 4 p.m. at Manor Township Volunteer Firehall, 167 Byron St., McGrann. Appointments: 800-733-2767 or visit redcrossblood.org and search for manortwpvfc.

Saturday : The Pa. Fish and Boat Commission will offer a Basic Boating Course from 8 a.m. to 4 p.m. at the Armstrong County Fire School, 1999 Route 66. Upon successful completion, students will be able to apply to the state with $10 and the proper paperwork for their Pa. Boating Safety Certificate with the state Fish Commission. Those attending should bring a bagged lunch, paper and pen. Reservation deadline: May 6. Reservations: email name, address and telephone number to jeburns@co.armstrong.pa.us.

McCandless

Wednesday: The Sealarks Womens Group will meet at 1 p.m. at Memorial Park Church, 8800 Peebles Road. The group provides Christian fellowship and social activity for women who are widowed, divorced or never married. Sandy Ritchey and her dog Wendell will present a program about therapy dogs. New members and guests welcome. Details and reservations: 412-487-7194.

New Kensington

Tuesday: The Community Clothes Closet, 1129 Kenneth Ave., will be open from 11 a.m. to 1 p.m. today and noon to 2 p.m. Tuesday. Note the change in days and times. Items available include clothing, shoes, purses, linens, blankets and Mary Queen of Apostles School uniforms. Donations are accepted during open hours.

Saturday : Vendor applications are being accepted by Knead Community Caf for an outdoor Mother Natures Garden Market at the caf. Items must be natural of plant-based products or garden related. No hot food vendors. Rain or shine. Details and applications: kneadcommunitycafe.org/vendorapplication.

May 17: East Kensington Community Circle is accepting orders for its Election Day beef vegetable soup sale. Cost: $8 per quart. Pickup: May 17 at the Community Circle Building, 1785 Seventh St. Road. Advance orders strongly recommended. Orders: Judy, 724-339-7887.

May 18: St. George Orthodox Church is accepting orders for a kibbee sale. Cost: $50 per dozen or six for $27. Order deadline: Wednesday. Pickup: 12:30 to 2:30 p.m. May 18 in the church hall, 1150 Leishman Ave. Orders: 724-337-3918.

North Apollo

May 21: North Apollo Volunteer Fire Department is accepting vendor applications for a crafter, vendor and food truck event planned at the firehall, 311 16th St. Applications: kingal0103@gmail.com or rachelann1975@yahoo.com.

Oakmont

Tuesdays: Taking Pounds Off Sensibly (TOPS) meets at 6 p.m. at Oakmont United Methodist Church, 419 Maryland Ave. Monthly dues: $5; first meeting is free. Details: vrevilla@pointpark.edu.

Plum

May 18: Plum Community Library will offer a free screening of the movie, Encanto, at 6 p.m. at the library, 445 Center New Texas Road. Reservations required. Reservations: visit the calendar section at plumlibrary.org.

May 19: The SOS Ministry at Holy Family Parish , 2000 Oblock Road, will offer a free program, What My Family Should Know, at 1 p.m. in the Our Lady of Joy Church hall. Attorney Jake Noble will discuss legal documents and papers you should have in place for your family. Reservations required. Reservations: 412-793-4511, ext. 107 or sos@holyfamilypgh.org.

Springdale

Wednesday and Thursday:Springdale Free Public Library will sponsor a plant exchange at 6 p.m. at the library, 331 School St. Bring your extra plants and exchange them with others. Details: 724-274-9729.

May 18: Springdale Free Public Library will offer a craft workshop to make a Memorial Day Mason jar candle at 1 p.m. at the library, 331 School St. Reservations required. Reservations: 724-274-9729.

Tarentum

Tuesday: Alcoholics Anonymous will meet from 7 to 8 p.m. at Central Presbyterian Church, 305 Allegheny St. An opportunity for silent prayer will be at 6:30 p.m.

Wednesday: The Elks will host bingo at 7 p.m. at the lodge, 219 E. Sixth Ave. The kitchen is open to the public from 5 to 8:30 p.m. Wednesdays, Thursdays and Fridays. Menu: elks644.org/elks-kitchen-1. Orders: 724-226-1644 by 8:15 p.m.

Vandergrift

Tuesday: A Board Game Night for students who are at least in fourth grade will be from 5:30 to 7:30 p.m. at the library, 128C. Washington Ave. All skill levels welcome. Details: 724-568-2212.

Tuesday: The YoYos Needles Art group at Vandergrift Public Library will meet from 5:30 to 7 p.m. in the library reading room, 128C. Washington Ave. All skill levels welcome. Details: 724-568-2212.

Wednesday : Vandergrift Public Library will have a free Toddler Time for children 4 and younger at 11 a.m. at the library, 128C Washington Ave. Reservations required. Reservations: 724-568-2212.

May 21: Vandergrift Presbyterian Church is accepting donations for a rummage sale. Hours: 9 a.m. to noon Mondays through Thursdays at the church, 195 Washington Ave. Please no televisions, furniture, computers or suitcases without wheels.

Washington Township

Wednesday: Poke Run Presbyterian Church will have a free soup luncheon at noon at the church, 1091 Poke Run Church Road. Doors open at 11:30 a.m. Details: 724-327-5563.

Wednesday: Alcoholics Anonymous will meet at 6 p.m. at Union Presbyterian Church, 656 Route 380.

West Deer

Wednesday: East Union Presbyterian Church will have a takeout spaghetti dinner from 4 to 7 p.m. at the church, 292 East Union Road. Menu: spaghetti with choice of meat, meatball or mushroom sauce, salad, rolls and dessert. Donations will be accepted. Details: 724-265-1381.

May 19: Union Presbyterian Church, 656 Route 380, is accepting orders for a hoagie sale. Cost: $8. Order deadline: Sunday. Pickup: 10:30 a.m. to 2 p.m. May 19 at the back of the church. Orders: 412-398-7603.

Read more from the original source:
The Stroller, May 9, 2022: Events in the Alle-Kiski Valley - TribLIVE

Back to Top